Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 253

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 253
---
 GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee           
 for the treatment of painful injuries to articular knee cartilage.                                                                       |

| b. | Transaction with OceanTech Corp. |

On May 2, 2023, OceanTech Acquisitions
I Corp., a Delaware corporation (“OceanTech”), R.B. Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of
OceanTech (“Merger Sub”), Aspire Acquisition LLC, OceanTech’s sponsor (the “Sponsor”), and the Company
executed a definitive Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which, among other things, Merger
Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary
of OceanTech. In May 2024, due to OceanTech not meeting certain Nasdaq compliance requirements, the Company and OceanTech couldn’t
proceed with the Merger and, as a result, the Merger Agreement was cancelled.

| c. | Forward share split |

On March 20, 2025, the Company effected a two and a half-for-one (2.5-for-1)
forward share split of its ordinary shares, no par value (the “Ordinary Shares”), and all classes of its preferred shares (the
“Split”). As a result of the Split, each one (1) Ordinary Share or preferred share, as applicable, issued and outstanding
at the time of the Split, was split into two and a half (2.5) Ordinary Shares or preferred shares, as applicable. All outstanding securities
entitling their holders the right to purchase Ordinary Shares, including, warrants and share options, were adjusted as a result of the
Split, as required by the terms of those securities. All share amounts, share prices, and exercise prices have been adjusted retroactively
within these financial statements to reflect the Split. On March 20, 2025, at the general meeting of the Company's shareholders, the shareholders
of the Company approved an increase of the authorized share capital of the Company and cancellation of the par value of the Ordinary Shares
and the Company’s preferred shares (see Note 15).

| d. | Going concern and management plans |

The accompanying financial statements
have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. Since